Real-life data of immune recovery using bictegravir/emtricitabine/tenofovir alafenamide in virologically suppressed people living with HIV. Results at 48–96 weeks of RETROBIC Study

Abstract Background Switching strategy with bictegravir/emtricitabine/tenofovir alafenamide (B/F/TAF) has become a gold standard for people living with HIV (PLWH), achieving high efficacy and safety rates. However, data regarding immune status in long-term real-life cohorts of pretreated patients ar...

Full description

Saved in:
Bibliographic Details
Published in:Journal of antimicrobial chemotherapy 2024-03, Vol.79 (3), p.595-607
Main Authors: Troya, Jesús, Pousada, Guillermo, Micán, Rafael, Galera, Carlos, Sanz, José, de los Santos, Ignacio, Dueñas, Carlos, Cabello, Noemí, Martín, Cristina, Galindo, María Josefa, Garcinuño, María Ángeles, Pedrero-Tomé, Roberto, Buzón, Luis
Format: Article
Language:English
Subjects:
Adenine - therapeutic use
Aged
Alanine
Amides
Drug Combinations
Emtricitabine - therapeutic use
Female
Heterocyclic Compounds, 3-Ring
Heterocyclic Compounds, 4 or More Rings - therapeutic use
HIV Infections - drug therapy
Humans
Male
Middle Aged
Piperazines
Pyridones
Retrospective Studies
RNA
Tenofovir - analogs & derivatives
Treatment Outcome
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Abstract Background Switching strategy with bictegravir/emtricitabine/tenofovir alafenamide (B/F/TAF) has become a gold standard for people living with HIV (PLWH), achieving high efficacy and safety rates. However, data regarding immune status in long-term real-life cohorts of pretreated patients are needed. Methods We performed a multicentre, non-controlled, retrospective study in virologically suppressed PLWH switching to B/F/TAF. We evaluated CD4+, CD8+ and CD4+/CD8+ ratio, efficacy and safety at weeks 48 and 96. Results The study comprised 1966 PLWH from 12 hospitals in Spain, of whom 80% were men, and the median age was 51.0 [42.0–57.0] years. The median time of HIV infection was 18.0 [10.0–27.0] years. No significant changes in CD4+, CD8+ T cells, or CD4+/CD8+ were observed after 96 weeks. Nevertheless, in women at weeks 48 and 96, we found a significant increase of CD4+ T cells and a significant decrease in CD8+ T cells. In patients ≥60 years at week 96, CD4 T cells significantly increased and CD8+ T cells significantly decreased at week 48. The on-treatment analysis revealed HIV-RNA
ISSN:0305-7453
1460-2091
1460-2091
DOI:10.1093/jac/dkae011